from the us study results

read into this what u will but the trading the volume the price reached tells me theres more to this then traders driving it .


The FMCG company’s stated objective in the Agreement with OBJ was to achieve up to a 10-
fold increase in drug delivery over an existing commercial product. Under the terms of the
Agreement, OBJ is restricted from disclosing any information relating to the drug tested, the
comparative product or the market.

obj being evaluated currently ?
OBJ is restricted from disclosing any information relating to the drug tested, the
comparative product or the market.
if thats the case is there several steps to be taken within ?
and have they progressed to next level ?
just some things to think about any thoughts re above are welcome